17.60CHF+1.73%Mkt Cap: 255.66M CHFP/E: —Last update: 2026-05-13
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Euro…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)22.05
PEG—
P/B-86.87
P/S3.24
EV/EBITDA-7.89
EV/Revenue3.33
EPS (TTM)-3.78
EPS (Forward)0.78
Cash Flow & Leverage
FCF Yield-13.94%
FCF Margin-46.17%
Operating CF-34.76M CHF
CapEx (TTM)52.00K CHF
Net Debt/EBITDA-0.81
Net Debt26.51M CHF
Technical
SMA 5016.42 (+7.2%)
SMA 20013.64 (+29.0%)
Beta-0.34
S&P 52W Chg24.23%
Avg Vol (30d)116.07K
Avg Vol (10d)111.32K
Technical Indicators
RSI (14)55.8
MACD0.2445
MACD Signal0.3045
MACD Hist.-0.0600
BB Upper18.46 CHF
BB Middle17.33 CHF
BB Lower16.19 CHF
BB Width13.08%
ATR (14)0.9794 CHF
Vol Ratio (20d)1.20x
52W Range
9.38087% of range18.84
52W High18.84 CHF
52W Low9.380 CHF
Profitability
Gross Margin19.66%
EBITDA Margin-42.15%
Profit Margin-63.79%
Oper. Margin-4.08%
ROE416.69%
ROA-33.25%
Revenue Growth112.70%
Earnings Growth—
Balance Sheet
Debt/Equity-4.14
Current Ratio1.29
Quick Ratio0.78
Book Value/Sh-0.1980 CHF
Cash/Share1.675 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 8, 2022
Splits
Last Split1:10
Split DateJul 3, 2023
Ownership
Shares Out.14.53M
Float10.56M
Insiders15.26%
Institutions9.20%
Analyst Consensus
Rating—
Target (Mean)30.00 CHF
Target Range30.00 CHF – 30.00 CHF
# Analysts1
Company
Market Cap255.66M CHF
Enterprise Value256.88M CHF
Revenue (TTM)77.19M CHF
Gross Profit15.17M CHF
Net Income (TTM)-49.24M CHF
Revenue/Share5.931 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees93
Last Price17.60 CHF
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0027148649